glp-1 drugs pharmaceutical companies partnerships 2025 Pipeline Update: February - Prime Therapeutics What's next for GLP-1 innovation:

Anemia is multifactorial, arising from defective CCO activity in erythrocyte precursors (normocytic anemia) and, in the case of TTM, from CP dysfunction, leading to iron retention and sideroblastic features [224, 244]

Tobacco toxins induce osteoporosis through ferroptosis

In LSS, the expression of the E3 ubiquitin ligase Smurf1 is markedly elevated, which promotes fibrosis and oxidative stress in LF cells, contributing to the progression of LSS by facilitating the ubiquitination and degradation of NRF2 [112]

This review also addresses recent advances in the development of other dual and triple receptor agonists